BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

✍ Scribed by Seiji Nagashima; Hiroshi Soda; Mikio Oka; Takeshi Kitazaki; Ken Shiozawa; Yoichi Nakamura; Masaaki Takemura; Hikaru Yabuuchi; Minoru Fukuda; Kazuhiro Tsukamoto; Shigeru Kohno

• Book ID: 105992374
• Publisher: Springer
• Year: 2006
• Tongue: English
• Weight: 304 KB
• Volume: 58
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-006-0212-y